BioSyent (CVE:RX) Sets New 52-Week High – Time to Buy?

Shares of BioSyent Inc. (CVE:RX) hit a new 52-week high during trading on Friday . The stock traded as high as C$11.98 and last traded at C$11.95, with a volume of 1111 shares changing hands. The stock had previously closed at C$11.61.

BioSyent Price Performance

The stock has a market cap of C$138.50 million, a PE ratio of 19.35 and a beta of 0.93. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13. The business has a 50 day moving average price of C$11.19 and a two-hundred day moving average price of C$10.51.

Insider Buying and Selling at BioSyent

In related news, Senior Officer Robert Joseph March sold 4,775 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of C$11.65, for a total value of C$55,628.75. Also, insider FAX Capital Corp. sold 230,800 shares of BioSyent stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00. Insiders have sold a total of 239,132 shares of company stock worth $2,661,482 over the last three months. 33.65% of the stock is currently owned by insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.